Demegen Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

  • Investments
  • 1

Demegen General Information

Description

Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fungi. The company develops products for the treatment of dermatological, vaginal, respiratory, ophthalmic and oral diseases with the peptides bind to and kill harmful microorganisms.

Contact Information

Website
www.demegen.com
Formerly Known As
Demeter BioTechnologies
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Par Advance Technologies
Corporate Office
  • 100 Technology Drive
  • Suite 440B
  • Pittsburgh, PA 15219
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Demegen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.

Request a free trial

Demegen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fun
Biotechnology
Pittsburgh, PA
000
000000&0 000

00000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
0000 000000000
New York, NY
00 As of 0000
000.00
000000000000 000.00

0000 0

modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
0000000000000
New York, NY
0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Demegen Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ember Therapeutics Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
Cell Source Corporation New York, NY 0000
Myriad Genetics Corporation Salt Lake City, UT 0000 00000 00000000 00000
Sangamo Therapeutics Formerly VC-backed Richmond, CA 000 00000 00000000 00000
Fore Biotherapeutics Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

Demegen Patents

Demegen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20020022048-A1 Bioerosable film; adhesion to mucous membranes Inactive 26-May-2000 000000000 0
US-6528488-B2 Therapy of cystic fibrosis in a mammal by administering mammal an effective amount of a histatin or its fragment Inactive 08-Jan-1999 00000000000 0
US-20020077282-A1 Therapy of cystic fibrosis in a mammal by administering mammal an effective amount of a histatin or its fragment Active 08-Jan-1999 00000000000
EP-1328234-A1 Methods for treating cystic fibrosis Inactive 08-Jan-1999 00000000000 0
CA-2360381-A1 Methods for treating cystic fibrosis Inactive 08-Jan-1999 C07K14/4723
To view Demegen’s complete patent history, request access »

Demegen Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.

Request a free trial

Demegen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Periodontix 01-Jan-2001 0000000000 Other Pharmaceuticals and Biotechnology
To view Demegen’s complete acquisitions history, request access »

Demegen FAQs

  • When was Demegen founded?

    Demegen was founded in 1992.

  • Where is Demegen headquartered?

    Demegen is headquartered in Pittsburgh, PA.

  • What industry is Demegen in?

    Demegen’s primary industry is Biotechnology.

  • Is Demegen a private or public company?

    Demegen is a Private company.

  • What is Demegen’s current revenue?

    The current revenue for Demegen is 00000.

  • How much funding has Demegen raised over time?

    Demegen has raised $2M.

  • Who are Demegen’s investors?

    CEO Venture Fund and Stonewood Capital Management have invested in Demegen.

  • Who are Demegen’s competitors?

    Ember Therapeutics, Cell Source, Myriad Genetics, Sangamo Therapeutics, and Fore Biotherapeutics are some of the 8 competitors of Demegen.

  • When was Demegen acquired?

    Demegen was acquired on 04-Nov-2004.

  • Who acquired Demegen?

    Demegen was acquired by Par Advance Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »